A TRANSPLANT KIDNEY IS A PRECIOUS GIFT FROM DONOR TO RECIPIENT.
DONOR-DERIVED MDR-10X MAY PROTECT THE GIFT.
Medeor is developing groundbreaking cellular immunotherapy products for kidney transplant recipients, called the MDR-10X series. MDR-10X includes, but is not limited to, MDR-101 and MDR-102 for recipients of HLA-matched and HLA-mismatched, living donor transplants, respectively. One time treatment with a MDR-10X product is intended to preserve or improve transplant kidney function and minimize or eliminate the need for chronic anti-rejection drug therapy in kidney transplant recipients. MDR-10X can induce donor-specific immune tolerance that protects against transplant kidney rejection, while avoiding the toxic side-effects of standard anti-rejection, immunosuppressive drugs. MDR-10X is manufactured from stem and progenitor cells collected from the kidney donor and infused into the transplant recipient several days after the transplant surgery. Prior to MDR-10X infusion, the transplant recipient receives conditioning therapy to make room for the MDR-10X cells. Achievement of mixed chimerism, co-existence of donor and recipient blood cells, is at the heart of the MDR-10X mechanism of action.